GSK plc has announced that its Bexsero booster vaccine has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation is significant as it supports the inclusion of a single booster dose for individuals aged 10 years and older who were previously vaccinated with Bexsero at least two years earlier. The positive opinion emphasizes the importance of maintaining protection against invasive meningococcal disease (IMD) during adolescence, a critical period of increased disease risk.
GSK, a global biopharmaceutical company, focuses on uniting science, technology, and talent to combat diseases. The company operates under the SIC code 2834, which encompasses pharmaceutical preparations. GSK trades under the ticker symbols GSK and GLAXF on the NYSE and OTC exchanges, respectively. Recent filings include a Form 6-K dated November 13, 2026, where this announcement was made.
The filing states, "The recommendation is supported by data showing that immune memory established following primary vaccination in infancy can be boosted with a single dose up to 19 years later." This finding is crucial as it indicates that the booster could effectively enhance the immune response in adolescents who were vaccinated during infancy.
This development may significantly impact vaccination programs across Europe, particularly in countries with established infant MenB vaccination initiatives. Sanjay Gurunathan, Senior Vice President of R&D Vaccines & Infectious Diseases at GSK, noted, “As the first generation of children vaccinated against MenB in infancy reaches adolescence, today’s positive CHMP opinion supports maintaining protection with a single booster dose during a second period in life of increased disease risk.” This sentiment highlights the potential benefits of the booster in reducing the overall burden of IMD.
The filing does not specify what the next steps will be following this positive opinion from the CHMP. However, it is expected that GSK will work towards obtaining formal approval for the booster dose, which could lead to its inclusion in national vaccination programs.
Read Next
Cloudflare's Michelle Zatlyn Sells Over $1.5M in Shares
Zurn Elkay VP LaMotte Jeremy L Reports Stock Sale
XTI Aerospace CEO Jeremy Schneiderman Reports Stock Exchange
Jennifer Salinas acquires 366,529 shares in Cerence Inc.
Mentz Christian acquires 125,979 shares of Cerence Inc.
Cerence CEO Acquires 819,039 Shares in Stock Transaction










